Showing results (1-10 of 152) with videos related to
Sort By:
Pageof 16
Trends in Cancer|April 5, 2024
A big step for MYC-targeted therapiesDanielle F Atibalentja, Anja Deutzmann, Dean W FelsherOncotarget|April 21, 2016
BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemiaYulin Li, Anja Deutzmann, Peter S Choi, et al.Nanotheranostics|February 11, 2022
Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint TherapyChristina K Lee, Danielle F Atibalentja, Lilian E Yao, et al.Scientific Reports|November 16, 2019
Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation IndexYulin Li, Daniel Thomas, Anja Deutzmann, et al.Nature Reviews. Clinical Oncology|September 11, 2021
The MYC oncogene - the grand orchestrator of cancer growth and immune evasionRenumathy Dhanasekaran, Anja Deutzmann, Wadie D Mahauad-Fernandez, et al.Genes & Cancer|November 2, 2010
MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent MechanismsDean W FelsherCancer Research|May 3, 2008
Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?Dean W FelsherCell Cycle (Georgetown, Tex.)|August 25, 2006
Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse modelsDean W FelsherCurrent Opinion in Genetics & Development|April 28, 2004
Reversibility of oncogene-induced cancerDean W FelsherAPMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|October 7, 2008
Tumor dormancy and oncogene addictionDean W FelsherPageof 16